Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to < 120/80 mmHg Target?: A Protagonist View from SPRINT
Based on the main results of the Systolic Blood Pressure Intervention Trial (SPRINT), we strongly believe that older hypertensive patients at high cardiovascular (CV) risk should receive intensive treatment to a target systolic blood pressure (SBP) of < 120 mm Hg [1-2]. SPRINT tested the hypothesis that intensive treatment of SBP to a target of < 120 mm Hg would reduce clinical events more than standard treatment to a target of < 140 mm Hg. SPRINT enrolled persons age 50 years or greater with SBP 130-180 mm Hg (treated or untreated), and at high CV risk. In particular, SPRINT over enrolled high-risk subgroups, including those age ≥75 years (SPRINT-Senior), blacks, and those with chronic kidney disease (CKD) or cardiovascular disease (CVD). The mean 10-year Framingham CVD risk score for all participants was 20%.
- hypertension, high blood pressure
- blood pressure
- blood pressure measurement/monitoring
- clinical trial
- Received June 1, 2016.
- Accepted August 30, 2016.